Point-of-care HCV RNA testing improves hepatitis C testing rates and allows rapid treatment initiation among people who inject drugs attending a medically supervised injecting facility.

MacIsaac MB, Whitton B, Anderson J, Cogger S, Vella-Horne D, Penn M, Weeks T, Elmore K, Pemberton D, Winter RJ, Papaluca T, Howell J, Hellard M, Stoové M, Wilson D, Pedrana A, Doyle JS, Clark N, Holmes JA, Thompson AJ.

Hepatitis C Injecting Drug Use

Public health benefits of shifting from hospital-focused to ambulatory TB care in Eastern Europe: Optimising TB investments in Belarus, the Republic of Moldova, and Romania.

Kelly SL, Jaoude GJA, Palmer T, Skordis J, Haghparast-Bidgoli H, Goscé L, Jarvis SJ, Kedziora DJ, Abeysuriya R, Benedikt C, Fraser-Hurt N, Shubber Z, Cheikh N, Bivol S, Roberts A, Wilson DP, Martin-Hughes R

Tuberculosis (TB)

Eliminating hepatitis C in Australia: a novel model of hepatitis C testing and treatment for people who inject drugs at a medically supervised injecting facility.

MacIsaac MB, Whitton B, Hubble A, Cogger S, Penn M, Weeks A, Elmore K, Pemberton D, Anderson J, Howard R, McKeever U, Papaluca T, Hellard ME, Stoove M, Wilson D, Pedrana A, Doyle J, Clark N, Holmes J, Thompson AJ

Alcohol and Other Drugs Hepatitis C Injecting Drug Use

Frequent and unpredictable changes in COVID-19 policies and restrictions reduce the accuracy of model forecasts.

Houdroge F, Palmer A, Delport D, Walsh T, Kelly SL, Hainsworth SW, Abeysuriya R, Stuart RM, Kerr CC, Coplan P, Wilson DP, Scott N

COVID-19

How to do (or not to do)… health resource allocations using constrained mathematical optimization.

Stuart RM, Fraser-Hurt N, Shubber Z, Vu L, Cheik N, Kerr CC, Wilson DP

Cost optimisation analysis of the expanded programme for immunisation: balancing equity and coverage in Pakistan.

Houdroge F, Yunus H, Delport D, Stearns E, Palmer A, Naim A, Kashif A, Pyne HH, Scott N, Oelrichs R, Wilson D

Immunisation + Health Systems Strengthening